AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2.

Trial Details

NCT ID

NCT06219941

Phase

PHASE2

Sponsor

AstraZeneca

Status

RECRUITING

Cancer Type

Pancreatic Ductal Adenocarcinoma Pancreatic Cancer

Interventions

AZD0901
5-Fluorouracil
Leucovorin
l-leucovorin
Irinotecan
Nanoliposomal Irinotecan

Locations (sample)

Orange, California, United States|33.78779,-117.85311
Palo Alto, California, United States|37.44188,-122.14302
Santa Rosa, California, United States|38.44047,-122.71443
Louisville, Kentucky, United States|38.25424,-85.75941
Commack, New York, United States|40.84288,-73.29289

Key Eligibility Criteria

Participant must be ≥ 18 years or the legal age of consent at the time of signing the ICF.
Participants who are CLDN18.2 positive.
Must have at least one measurable lesion according to RECIST v1.1.
ECOG performance status of 0 to 1 with no deterioration over the previous 2 weeks prior first day of dosing.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →